Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KCNN4 | O15554 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3996786 | 1.00 | MEN1 (0.41) | MEN1KMT2ASMN1; SMN2NPC1MAPT | |
| SCHEMBL4000723 | 1.00 | MEN1 (0.41) | MEN1KMT2ASMN1; SMN2NPC1MAPT | |
| SCHEMBL3997270 | 0.84 | SMN1; SMN2 (0.40) | MEN1KMT2ASMN1; SMN2NPC1MAPT | |
| SCHEMBL3999987 | 0.84 | SMN1; SMN2 (0.40) | MEN1KMT2ASMN1; SMN2NPC1MAPT | |
| SCHEMBL3961232 | 0.83 | CYP2C19 (0.47) | KMT2AMAPTKCNN4LMNAALDH1A1 | |
| SCHEMBL4006608 | 0.83 | CYP2C19 (0.47) | KMT2AMAPTKCNN4LMNAALDH1A1 | |
| SCHEMBL4005860 | 0.83 | CYP2C19 (0.47) | KMT2AMAPTKCNN4LMNAALDH1A1 | |
| SCHEMBL15109990 | 0.81 | MEN1 (0.43) | MEN1KMT2ASMN1; SMN2NPC1MAPT | |
| SCHEMBL5794046 | 0.81 | KDM4E (0.44) | MEN1KMT2ASMN1; SMN2NPC1MAPT | |
| SCHEMBL22164298 | 0.81 | KCNN4 (0.47) | MEN1KMT2ASMN1; SMN2NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538105-B2 | Anti-infective agents | ABBOTT LABORATORIES (US) | 2009-05-26 | — | — | US | disclosed |
| US-20080193413-A1 | Anti-Infective Agents | ABBOTT LABORATORIES (US) | 2008-08-14 | — | — | US | disclosed |
| US-7378414-B2 | Viricides for infections caused by an RNA-containing virus; enzyme inhibitors for a hepatitis C virus (HCV) polymerase; inhibiting HCV viral replication; liver cirrhosis; e. g., 3-(1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)-4-hydroxy-1,1-dipropyl-2(1H)-naphthalenone | ABBOTT LABORATORIES (US) | 2008-05-27 | — | — | US | disclosed |
| US-20050107364-A1 | Viricides for infections caused by an RNA-containing virus; enzyme inhibitors for a hepatitis C virus (HCV) polymerase; inhibiting HCV viral replication; liver cirrhosis; e. g., 3-(1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)-4-hydroxy-1,1-dipropyl-2(1H)-naphthalenone | ABBVIE INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2005019191-A2 | 1, 1-DIOXIDO-4H-1,2,4-BENZOTHIADIAZINE DERIVATE UND VERWANDTE VERBINDUNGEN ALS INHIBITOREN DER HCV POLYMERASE ZUR BEHANDLUNG VON HEPATITIS C | ABBOTT LABORATORIES (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080193413-A1 | Anti-Infective Agents | POLI, RPL5, POLRMT | MEN1 4787/4885KMT2A 4638/4885SMN1; SMN2 4453/4885 |
| US-20050107364-A1 | Viricides for infections caused by an RNA-containing virus; enzyme inhibitors for a hepatitis C virus (HCV) polymerase; inhibiting HCV viral replication; liver cirrhosis; e. g., 3-(1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)-4-hydroxy-1,1-dipropyl-2(1H)-naphthalenone | POLRMT, RNASE1, RNGTT | MEN1 4794/4885KMT2A 3557/4885SMN1; SMN2 3696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.